Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data
| العنوان: | Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data |
|---|---|
| المؤلفون: | Shu-Qiang Yuan, Run-Cong Nie, Wen-Wu Liu, Jie Zhou, Jin-Ling Duan, Guo-Ming Chen, Yuan Fang Li, Mu-Yan Cai, Yun Wang, Shi Chen |
| المصدر: | Journal of Immunotherapy (Hagerstown, Md. : 1997) |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | PD-L1, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Immunology, body mass index, Subgroup analysis, Overweight, survival, immune checkpoint inhibitors, Renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Internal medicine, Clinical Studies, PD-1, medicine, Humans, Immunology and Allergy, Prospective Studies, Lung cancer, Retrospective Studies, Pharmacology, business.industry, Hazard ratio, Retrospective cohort study, medicine.disease, Kidney Neoplasms, Confidence interval, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, medicine.symptom, business, Body mass index |
| الوصف: | Supplemental Digital Content is available in the text. Despite that immune checkpoint inhibitors (ICIs) had tremendous improved the survival of multiple solid tumors, only a limited proportion of patients are responsive to ICIs. Therefore, effective variables are urgently needed to predict the probability of response to ICIs. Systematic searches were conducted from inception up to May, 2020. Prospective or retrospective studies of ICIs that investigated the association between body mass index (BMI) and survival outcomes, including overall survival (OS) and/or progression-free survival (PFS), were selected. The association between each BMI category and survival outcomes was calculated using Cox proportional hazard regression models and quantified as hazard ratio (HR) with corresponding 95% confidence interval. Seven clinical studies involving data from 3768 individual patients were included. The median OS was 15.5 months (95% confidence interval: 14.7–16.2 mo) and the median PFS was 5.7 months (5.2–6.3 mo). The median OS was significantly longer in overweight/obese patients than in nonoverweight patients (20.7 vs. 11.3 mo; P |
| تدمد: | 1524-9557 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b783562020e927331312d9c755945f https://doi.org/10.1097/cji.0000000000000389 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....23b783562020e927331312d9c755945f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15249557 |
|---|